Loading company
Turn Therapeutics Inc.
TTRX · Nasdaq · ·
$13.52+3.5%Sep 29 close
- 1M
- +37.4%
- 6M
- +319.9%
TTRX · Nasdaq · ·
$13.52+3.5%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$5.8M | -$1.2M | -371.59% |
| Profit per share | -$0.20 | -$0.05 | -300.00% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Turn Therapeutics Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Turn Therapeutics is a clinical-stage biotechnology company focused on developing targeted, localized therapies for inflammatory and infectious skin diseases. GX-03 is Turn Therapeutics’ lead investigational topical candidate being developed as a targeted, non-systemic treatment for atopic dermatitis, designed to deliver biologic-level efficacy without the trade-offs of injectable administration or systemic immunosuppression.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Turn Therapeutics Inc.’s Item 2.02 8-K filed August 12, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.